Skip to main navigation Skip to search Skip to main content

Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial

  • FIND-CKD investigators
  • Department of Clinical Pharmacy and Pharmacology
  • University of Groningen
  • Department of Medicine
  • Indiana University Bloomington
  • Center for Clinical Cancer Genetics and Global Health
  • The University of Chicago
  • Ellen and Martin Prosserman Centre for Neuromuscular Diseases
  • University Health Network
  • National Heart Centre Singapore
  • Duke-NUS Graduate Medical School
  • Renal and Metabolic Division
  • University of New South Wales
  • Department of Renal Medicine
  • Royal North Shore Hospital
  • 1st Department of Nephrology
  • Aristotle University of Thessaloniki
  • Providence Inland Northwest Health
  • Nephrology Division
  • University of Washington
  • Department of Clinical Research and Epidemiology
  • University of Würzburg
  • Bayer AG
  • Bayer Pharmaceuticals

Research output: Contribution to journal › Article › peer-review

79 Scopus citations

Fingerprint

Dive into the research topics of 'Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science